Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 2, 2003, Pages 653-657

  Hu, Yanmin ^a   Coates, Anthony R M ^a,b   Mitchison, Denis A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b BioTherapies Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOSTERILANT; CIPROFLOXACIN; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; INCUBATION TIME; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TIME SERIES ANALYSIS;

ANTI-INFECTIVE AGENTS; ANTIBIOTICS, ANTITUBERCULAR; CELL SURVIVAL; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; STERILIZATION;

EID: 0037311481     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.2.653-657.2003     Document Type: Article

References (16)

1. Alvirez-Freites, E. J., J. L. Carter, and M. H. Cynamon. 2002. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:1022-1025.
2. Coates, A., Y. Hu, R. Bax, and C. Page. 2002. The future challenges facing the development of new antimicrobial drugs. Nat. Rev. Drug Discovery 1:895-910.
3. Global Alliance for Tuberculosis Drug Development. 2001. Tuberculosis scientific blueprint for TB drug development. Tuberculosis 81(Suppl. 1):1-52.
4. Hu, Y., and A. R. M. Coates. 2001. Increased levels of sigJ mRNA in late stationary phase cultures of Mycobacterium tuberculosis detected by DNA array hybridisation. FEMS Microbiol. Lett. 202:59-65.
5. Hu, Y., J. A. Mangan, J. Dhillon, K. M. Sole, D. A. Mitchison, P. D. Butcher, and A. R. M. Coates. 2000. Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J. Bacteriol. 182:6358-6365.
6. Ji, B., N. Lounis, C. Maslo, C. Truffot-Pernot, P. Bonnafous, and J. Grosset. 1998. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42:2066-2069.
7. Jindani, A., V. R. Aber, E. A. Edwards, and D. A. Mitchison. 1980. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 121:939-949.
8. Lalande, V., C. Truffot-Pernot, A. Paccaly-Moulin, J. Grosset, and B. Ji. 1993. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob. Agents Chemother. 37:407-413.
9. Lounis, N., A. Bentoucha, C. Truffot-Pernot, B. Ji, R. O'Brien, A. Vernon, G. Roscigno, and J. Grosset. 2001. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob. Agents Chemother. 45:3482-3486.
10. Mitchison, D. A. 1992. The Garrod Lecture. Understanding the chemotherapy of tuberculosis - current problems. J. Antimicrob. Chemother. 29:477-493.
11. Mitchison, D. A. 2000. Role of individual drugs in the chemotherapy of tuberculosis. Int. J. Tuberc. Lung Dis. 4:796-806.
12. O'Brien, R. J., and P. P. Nunn. 2001. The need for new drugs against tuberculosis: obstacles, opportunities, and next steps. Am. J. Respir. Crit. Care Med. 162:1055-1058.
13. Sirgel, F. A., F. J. Botha, D. P. Parkin, B. W. Van de Wal, R. S. Schall, P. R. Donald, and D. A. Mitchison. 1997. The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 156:901-905.
14. Sirgel, F. A., P. R. Donald, J. Odhiambo, W. Githui, K. C. Umapathy, C. N. Paramasivan, C. M. Tam, K. M. Lam, C. W. Lam, K. M. Sole, D. A. Mitchison, and the EBA Collaborative Study Group. 2000. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J. Antimicrob. Chemother. 45:859-870.
15. Tuberculosis Research Centre (Indian Council of Medical Research), Chennai. 2002. Shortening short course chemotherapy: a randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian J. Tuberc. 49:27-38.
16. Wayne, L. G., and L. G. Hayes. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64:2062-2069.